Multi-functional immune-modulating antibody therapeutics for autoimmune disease

IMMUNOLOGY N	on-Clinical
Product Type	Immunoglobulin product (Bispecific antibody)
Indication	Rheumatoid Arthritis à Autoimmune disease (IBD, SLE, etc)
Target	OX40L and TNF
MoA(Mechanism of Action)	Dual modulation of inflammatory cytokine & adaptive immune response → Rebalancing immune system lead long-term immune homeostasis Dual modulation of inflammatory cytokine & adaptive immune responses
	Inflammatory Cytokines Pro-inflammatory Cytokines RA Patient Unit-inflammatory Cytokines Treated Immuno (nti-INF & anti-OX40L) Adaptive Responses Effector Muto-antibodies Auto-antibodies Immuno cells Immuno cells Inappropriate activation of pro-inflammatory cytokines and effector immune cells Immuno cells Immuno cells Immuno cells
Competitiveness	 Superior efficacy compared to existing treatments through simultaneous control of inflammatory cytokine and adaptive immunity Robust response rate without paradoxical effect Increase remission rate and provide fundamental treatment options through immune system rebalancing and autoantibody reduction Reduction of systemic side effects through disease site specific action
Development Stage	Non-Clinical
Route of Administration	Parenteral-Subcutaneous / Intravenous



IMBiologics